Form D · Biotechnology
Mellitus, LLC
Boston, MA · CIK 0001588301
Offering snapshot reported Aug 31, 2023 · SEC filing
- Reported sold
- $90K Offering amount: $750K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 21, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 31, 2023 | Initial | $90,000 | No comparison | 2 | SEC filing |
| May 7, 2019 | Initial | $2,802,306 | No comparison | 11 | SEC filing |
| Oct 2, 2018 | Initial | $1,675,000 | No comparison | 6 | SEC filing |
| Aug 13, 2018 | Initial | $1,749,999 | No comparison | 2 | SEC filing |
| May 3, 2018 | Initial | $5,593,558 | No comparison | 39 | SEC filing |
| May 8, 2017 | Amendment | $2,066,516 | $1,154,425vs Mar 2, 2017 | 26 | SEC filing |
| Mar 2, 2017 | Initial | $912,091 | No comparison | 20 | SEC filing |
| May 24, 2016 | Initial | $992,883 | No comparison | 25 | SEC filing |
| Jan 4, 2016 | Initial | $50,000 | No comparison | 3 | SEC filing |
| Sep 28, 2015 | Initial | $150,000 | No comparison | 2 | SEC filing |
| Aug 20, 2015 | Initial | $558,934 | No comparison | 13 | SEC filing |
| Oct 3, 2013 | Initial | $2,217,491 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-491185
Source: Form D, filed Aug 31, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Chorev | Director |
| Christopher De Souza | Director |
| Jose Halperin | Director |
| Edwin Henrie, Ii | Director |
| Joyce A. Lonergan | Director, Executive |
| Ellie Mc Guire | Director |
| Gail Page | Director |
| John Tagliamonte | Director, Executive |
| Xing Zhao | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Cic Boston, 16th Floor 50 Milk Street
Boston, MA, 02109
Boston, MA, 02109